Therapeutic Solutions International Announces the Licensing of Exosome Technology to MolecuVax, Inc

OCEANSIDE, CA–(Marketwired – February 08, 2016) – Therapeutics Solutions International, Inc., (OTC PINK: TSOI) announced today that the Company has licensed their Exosome Patent to MolecuVax, Inc. (“MVAX”) a wholly owned subsidiary of Therapeutic Solutions International, Inc. (“TSI”) where the intellectual property owned by TSI surrounding immune-oncology is housed. The programs within MVAX include using exosomes derived from various immune cells to attack cancers as well as developing a cancer vaccine against cancers that express a certain protein unique to them.

The Company filed on November 20, 2015, a Patent Application titled “Exosome Mediated Innate and Adaptive Immune Stimulation for Treatment of Cancer,” a patent on means of manufacturing exosomes that possess high concentrations of proteins found on tumors, which are specifically optimized to stimulate the immune system of cancer patients as a new form of immunotherapy.

“TSI is developing a range of immune-modulatory agents to target certain cancers, improve maternal and fetal health, and for overall daily well being. Licensing this technology to our subsidiary MolecuVax is an important step that will allow the invention to mature, while also furthering our other programs within OmniBiome our subsidiary focused on fetal-maternal health issues,” said Timothy Dixon, CEO of TSOI.

“Activating one’s immune system is now a well-accepted method to effectively treat certain cancers, reduce recovery time from viral or bacterial infections and to prevent illness. On the other hand, inhibiting one’s immune system is vital for reducing inflammation, autoimmune disorders and allergic reactions,” added Dr. Thomas Ichim, Director of TSOI.

About Therapeutic Solutions International, Inc.
The Company’s corporate website is Our new products can be viewed on and products can be ordered at

Source – Marketwired

Leave a Reply

Your email address will not be published. Required fields are marked *